In short Article

No melatonin for primary sleep disorders


Even though it has been known for years that melatonin has limited efficacy for the treatment of primary sleep disorders, this agent is still frequently used for this purpose. Recent randomised studies and meta-analyses have also found only minimal, clinically irrelevant efficacy. This confirms once more that melatonin should not be recommended or prescribed for primary sleep disorders. Nor should melatonin be used as a sleep-inducing agent in the form of self-care medicines or dietary supplements.

  • In the last 10 years, no supplementary evidence has been published to support the prescription of melatonin for primary sleep disorders.
  • There are enough arguments for doctors, pharmacists and other care providers to discourage the use of melatonin to treat primary sleep disorders in adults.

  1. Bijl D. Melatonine (Circadin®), primaire insomnia bij patiënten van 55 jaar en ouder. Gebu. 2009;43(8):80-81.
  2. Nederlands Huisartsen Genootschap. NHG-Standaard Slaapproblemen en slaapmiddelen. M23 2014. Via: https://www.nhg.org/standaarden/volledig/nhg-standaard-slaapproblemen-en-slaapmiddelen. Geraadpleegd op 12-02-2020.
  3. Zorginstituut Nederland. Farmacotherapeutisch Kompas. Via: https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/m/melatonine#advies. Geraadpleegd op 12-02-2020
  4. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675–700. doi:10.1111/jsr.12594
  5. Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol. 2019;33(8):923–947. doi:10.1177/0269881119855343
  6. Low TL, Choo FN, Tan SM. The efficacy of melatonin and melatonin agonists in insomnia - An umbrella review. J Psychiatr Res. 2020;121:10–23. doi:10.1016/j.jpsychires.2019.10.022
  7. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:51. Published 2010 Aug 16. doi:10.1186/1741-7015-8-51
  8. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27(1):87–98. doi:10.1185/03007995.2010.537317
  9. Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10–22. doi:10.1016/j.smrv.2016.06.005
  10. Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence. Complement Ther Med. 2019;42:65–81. doi:10.1016/j.ctim.2018.11.003
  11. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781–788. doi:10.7326/0003-4819-141-10-200411160-00009
  12. College ter Beoordeling van Geneesmiddelen. Geneesmiddeleninformatiebank. Via: https://www.geneesmiddeleninformatiebank.nl/nl/. Geraadpleegd op 23-02-2020.
  13. Inspectie Gezondheidszorg en Jeugd. Veel gestelde vragen over melatonine. Via: https://www.igj.nl/documenten/vragen-en-antwoorden/veelgestelde-vragen-over-melatonine. Geraadpleegd op 20-02-2020.
  14. Erland LA, Saxena PK. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. J Clin Sleep Med. 2017;13(2):275–281. Published 2017 Feb 15. doi:10.5664/jcsm.6462
  15. EMA. SmPC Melatonine. Via: https://www.ema.europa.eu/en/documents/product-information/circadin-epar-product-information_en.pdf. Geraadpleegd op 15-01-2020.
  16. Sharma M, Palacios-Bois J, Schwartz G, et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry. 1989;25(3):305–319. doi:10.1016/0006-3223(89)90178-9
  17. Keijzer H, Smits MG, Duffy JF, Curfs LM. Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders. Sleep Med Rev. 2014;18(4):333–339. doi:10.1016/j.smrv.2013.12.001
  18. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901–909. doi:10.1007/s00228-015-1873-4
  19. Andersen LP, Werner MU, Rosenkilde MM, et al. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol. 2016;17:8. Published 2016 Feb 19. doi:10.1186/s40360-016-0052-2
  20. Zetner D, Andersen LP, Rosenberg J. Pharmacokinetics of Alternative Administration Routes of Melatonin: A Systematic Review. Drug Res (Stuttg). 2016;66(4):169–173. doi:10.1055/s-0035-1565083

Authors

  • Leo M.L. Stolk, dr